<!doctype html>
<html lang="en" manifest="cache.manifest">
  <head>
    <!-- Global site tag (gtag.js) - Google Analytics -->
    <script async src="https://www.googletagmanager.com/gtag/js?id=G-E7V5SQE1XT"></script>
    <script>
      window.dataLayer = window.dataLayer || [];
      function gtag(){dataLayer.push(arguments);}
      gtag('js', new Date());

      gtag('config', 'G-E7V5SQE1XT');
    </script>
    
    <link rel="manifest" href="manifest.json">
    <!-- Required meta tags -->
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">

    <!-- Bootstrap CSS -->
    <link rel="preconnect" href="https://fonts.gstatic.com">
    <link href="https://fonts.googleapis.com/css2?family=Montserrat:wght@100;200;300;400;500;600;700;800;900&display=swap" rel="stylesheet">
    
    <link rel="stylesheet" href="css/bootstrap.min.css">
    <link rel="stylesheet" href="css/style.css">

    <title>Agios</title>
  </head>
  <body>
    <nav class="navbar navbar-expand-lg navbar-dark">
      <div class="container">
        <a class="navbar-brand" href="index.html">
          <img src="images/logo.png" />
        </a>

          <ul class="navbar-nav ml-auto">
            <li class="nav-item active d-none d-md-block">
              <a class="nav-link"><span class="light-blue-text pr-3">Mitapivat (AG-348) Mechanism of Action</span></a>
            </li>
            <li class="nav-item active">
              <a class="nav-link" href="index.html">
                <img src="images/icons/home-icon.png" width="30">
              </a>
            </li>
            <li class="nav-item active">
              <a class="nav-link" href="peak-registry.html">
                <img src="images/icons/peak-registry-icon.png" width="30">
              </a>
            </li>
            <li class="nav-item active">
              <a class="nav-link" href="pkr-activator-pipeline.html">
                <img src="images/icons/pipeline-icon.png" width="30">
              </a>
            </li>
            <li style="display: none;">
              <a class="nav-link prev position-relative" href="#mitapivatCarousel" role="button" data-slide="prev">
                <img src="images/icons/prev.png" width="30">
              </a>
            </li>
            <li>
              <a class="nav-link next position-relative" href="#mitapivatCarousel" role="button" data-slide="next">
                <img src="images/icons/next.png" width="30">
              </a>
            </li>
          </ul>

          <div class="d-block d-md-none mt-2"><span class="light-blue-text pr-3">Mitapivat (AG-348) Mechanism of Action</span></div>
      </div>
    </nav>
    <main class="pipeline-details">
      <div class="container">
        <div id="mitapivatCarousel" class="carousel slide" data-ride="carousel"  data-interval="false">
          <div class="carousel-inner">
            <div class="carousel-item active" data-id="1">            
                <div class="row">
                  <div class="col-sm-12 col-12">
                    <h1 class="mb-4">Mitapivat (AG-348) Mechanism of Action</h1>
                  </div>
                </div>
                <div class="row">
                    <div class="col-md-8 mb-5">
                      <h3 class="font-weight-normal mb-3">Rationale for Development in PK Deficiency, Thalassemia and Sickle Cell Disease</h3>
                      <br/><br/><br/><br/><br/>
                      <h3 class="font-weight-normal mb-3">Disclaimer</h3>
                      <p>Mitapivat sulfate (mitapivat; AG-348) is an investigational agent and its safety and efficacy has not been established. There is no guarantee that mitapivat will receive health authority approval or become commercially available in any country for the uses being investigated.</p>
                    </div>
                </div>
                <footer>
                    <div class="row">
                      <div class="col-md-12">
                        <p class="text-right">MIT-ALL-0020 6/8/2020<br/>
                          For more information (physician/HCP only), please email medinfo@agios.com.<br/>
                          &copy;2021 Agios Pharmaceuticals, Inc. All rights reserved.</p>
                      </div>
                    </div>
                </footer>
            </div>
            <div class="carousel-item" data-id="2">
                <div class="row">
                  <div class="col-sm-12 col-12">
                    <h4 class="font-weight-normal mb-4">Pyruvate Kinase Red Blood Cell (PKR) Isoform: Structure and Function<sup>1,2</sup></h4>
                  </div>
                </div>
                <div class="row mb-3">
                    <div class="col-md-3">
                      <ul class="pt-8 mb-3">
                        <li>PKR is a 240 kDa tetramer</li>
                        <li>Binds to both PEP and FBP</li>
                        <li>Catalyzes the conversion of PEP to pyruvate, which
                          <ul class="pl-20">
                           <li>Generates 50% of ATP produced via glycolysis</li>
                          </ul>
                        </li>
                      </ul>
                    </div>
                    <div class="col-md-7">
                      <img src="images/mechanism-of-action/1.png" class="w-100">
                    </div>
                </div>
                <footer>
                    <div class="row">
                      <div class="col-md-6">
                        <p class="text-left mb-4"><strong>1. Kung et al., <i>Blood</i>, 2017; 130(11):1347-1356; 2. Grace R et al., <i>Am J Hematol</i> 2015;90(9):825-830.</strong></p>
                      </div>
                      <div class="col-md-6">
                        <p class="text-right">MIT-ALL-0020 6/8/2020<br/>
                          For more information (physician/HCP only), please email medinfo@agios.com.<br/>
                        ©2021 Agios Pharmaceuticals, Inc. All rights reserved.</p>
                      </div>
                    </div>
                </footer>
            </div>
            <div class="carousel-item" data-id="3">
                <div class="row">
                  <div class="col-sm-12 col-12">
                    <h4 class="font-weight-normal mb-4">Effect of Mutations on Pyruvate Kinase Activity: Multiple Mechanisms<sup>1</sup></h4>
                  </div>
                </div>
                <div class="row mb-2">
                    <div class="col-md-10 call-12">
                      <img src="images/mechanism-of-action/2.png" class="w-100">
                    </div>
                </div>
                <footer>
                    <div class="row">
                      <div class="col-md-6">
                        <p class="text-left mb-4"><strong>1. Kung et al., <i>Blood</i>, 2017; 130(11):1347-1356.</strong></p>
                      </div>
                      <div class="col-md-6">
                        <p class="text-right">MIT-ALL-0020 6/8/2020<br/>
                          For more information (physician/HCP only), please email medinfo@agios.com.<br/>
                        ©2021 Agios Pharmaceuticals, Inc. All rights reserved.</p>
                      </div>
                    </div>
                </footer>
            </div>
            <div class="carousel-item" data-id="4">
                <div class="row">
                  <div class="col-sm-12 col-12">
                    <h4 class="font-weight-normal mb-4">Mitapivat (AG-348) Activates Wild-Type and Mutant PKR<sup>1</sup></h4>
                  </div>
                </div>
                <div class="row mb-5">
                    <div class="col-md-4">
                      <img src="images/mechanism-of-action/3.png" class="w-100 mb-3">
                    </div>
                    <div class="col-md-4">
                      <img src="images/mechanism-of-action/4.png" class="w-100 mb-3">
                    </div>
                    <div class="col-md-4">
                      <img src="images/mechanism-of-action/5.png" class="w-100 mb-3">
                    </div>

                    <div class="col-md-12">
                      <ul class="pl-0">
                        <li>A. Mitapivat, a small molecule activator, binds at the dimer-dimer interface of the PKR tetramer</li>
                        <li>B. Mitapivat binding enhances the affinity of recombinant PKR for its substrate PEP</li>
                        <li>C. Mitapivat increases activity of recombinant wild-type and mutant PKR enzymes
                          <ul>
                            <li>Mitapivat increases PKR catalytic activity in cases in which the mutation results in decreased enzyme activity, e.g. R486W</li>
                            <li>Mitapivat increases PKR stability in cases in which the mutation reduces enzyme stability, e.g. R510Q</li>
                          </ul>
                        </li>
                      </ul>
                    </div>
                </div>
                <footer>
                    <div class="row">
                      <div class="col-md-6">
                        <p class="text-left mb-4">PEP = phosphoenolpyruvate<br/>
                          <strong>1. Kung et al., <i>Blood</i>, 2017; 130(11):1347-1356.</strong></p>
                      </div>
                      <div class="col-md-6">
                        <p class="text-right">MIT-ALL-0020 6/8/2020<br/>
                          For more information (physician/HCP only), please email medinfo@agios.com.<br/>
                        ©2021 Agios Pharmaceuticals, Inc. All rights reserved.</p>
                      </div>
                    </div>
                </footer>
            </div>
            <div class="carousel-item" data-id="5">
                <div class="row">
                  <div class="col-sm-12 col-12">
                    <h4 class="font-weight-normal mb-4">Mitapivat (AG-348) Increased PKR Activity and ATP Levels, and Decreased Upstream Accumulation of 2,3-DPG</h4>
                  </div>
                </div>
                <div class="row mb-0">
                    <div class="col-md-1"></div>
                    <div class="col-md-5">
                      <img src="images/mechanism-of-action/6.png" class="w-100 mb-3" style="width: 90%!important;">
                    </div>
                    <div class="col-md-1"></div>
                    <div class="col-md-3">
                      <img src="images/mechanism-of-action/7.png" class="w-100 mb-3" style="width: 90%!important;">
                    </div>
                </div>
                <footer>
                    <div class="row">
                      <div class="col-md-6">
                        <p class="text-left mb-4"><strong>1. Kung et al., <i>Blood</i>, 2017; 130(11):1347-1356; 2. Grace R et al., <i>Am J Hematol</i> 2015;90(9):825-830.</strong></p>
                      </div>
                      <div class="col-md-6">
                        <p class="text-right">MIT-ALL-0020 6/8/2020<br/>
                          For more information (physician/HCP only), please email medinfo@agios.com.<br/>
                        ©2021 Agios Pharmaceuticals, Inc. All rights reserved.</p>
                      </div>
                    </div>
                </footer>
            </div>
            <div class="carousel-item" data-id="6">
                <div class="row">
                  <div class="col-sm-12 col-12">
                    <h4 class="font-weight-normal mb-4">PKR Activators May Improve Thalassemic RBC Production and Survival by Increasing ATP Production</h4>
                  </div>
                </div>
                <div class="row mb-0">
                    <div class="col-md-10 col-12">
                      <img src="images/mechanism-of-action/8.png" class="w-100 mb-3">
                    </div>
                </div>
                <footer>
                    <div class="row">
                      <div class="col-md-6">
                        <p class="text-left mb-4"><strong>1. Kung C, et al. <i>Blood</i>. 2017;130(11):1347-1356; 2. Rab MAE, et al. <i>Blood</i>. 2019;134(Suppl 1): Abstract 3506; 3. Kuo KHM, et al. <i>American Society of Hematology Meeting 2020</i>; Presentation 2600; 4. Matte A, et al. <i>J Clin Invest</i>. 2021;131(10):e144206.</strong></p>
                      </div>
                      <div class="col-md-6">
                        <p class="text-right">For more information (physician/HCP only), please email medinfo@agios.com.<br/>
                        ©2021 Agios Pharmaceuticals, Inc. All rights reserved.</p>
                      </div>
                    </div>
                </footer>
            </div>
            <div class="carousel-item" data-id="7">
                <div class="row">
                  <div class="col-sm-12 col-12">
                    <h4 class="font-weight-normal mb-4">PKR Activation in Sickle Cell Disease Modulates 2,3-DPG and ATP to Improve Anemia and Reduce Sickling</h4>
                  </div>
                </div>
                <div class="row mb-0">
                    <div class="col-md-10 col-12">
                      <img src="images/mechanism-of-action/9.png" class="w-100 mb-3">
                    </div>
                </div>
                <footer>
                    <div class="row">
                      <div class="col-md-6">
                        <p class="text-left mb-4"><strong>1. Kung C, et al. <i>Blood</i>. 2017;130(11):1347-1356; 2. Rab MAE, et al. <i>Blood</i>. 2021;106(1):238-249.</strong></p>
                      </div>
                      <div class="col-md-6">
                        <p class="text-right">For more information (physician/HCP only), please email medinfo@agios.com.<br/>
                        ©2021 Agios Pharmaceuticals, Inc. All rights reserved.</p>
                      </div>
                    </div>
                </footer>
            </div>
            <div class="carousel-item" data-id="8">
                <div class="row">
                  <div class="col-sm-12 col-12">
                    <h4 class="font-weight-normal mb-4">Mitapivat Increased ATP and Improved RBC Parameters in the Hbb<sup>th3/+</sup> Mouse Model of β-thalassemia</h4>
                  </div>
                </div>
                <div class="row">
                    <div class="col-md-12">
                      <img src="images/mechanism-of-action/10.png" class="w-100 mb-3">
                      <h6 class="mb-4" style="font-size: 0.8rem;">Republished with permission of <i>J Clin Invest</i>, from <strong>The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model,</strong> Matte A, 131(10) 2021; permission conveyed through Copyright Clearance Center, Inc.</h6>
                      <ul class="pl-0">
                        <li>
                          <ul class="mb-5 pl-20">
                            <li>Mitapivat ameliorated anemia, increased Hb, and enhanced red blood cell survival after 21 days of oral treatment in the Hbb<sup>th3/+</sup> mouse model</li>
                            <li>Mitapivat reduced signs and markers of ineffective erythropoiesis and liver iron overload (data not shown)</li>
                          </ul>
                        </li>
                      </ul>
                    </div>
                </div>
                <footer>
                    <div class="row">
                      <div class="col-md-6">
                        <p class="text-left mb-4">*p<0.05 vs vehicle<br/>
                          ATP = adenosine triphosphate; Hbbth3/+ = heterozygote mouse model of β-thalassemia.<br/>
                          <strong>1. Matte A, et al. <i>J Clin Invest.</i> 2021;131(10):e144206</strong></p>
                      </div>
                      <div class="col-md-6">
                        <p class="text-right">For more information (physician/HCP only), please email medinfo@agios.com.<br/>
                        &copy;2021 Agios Pharmaceuticals, Inc. All rights reserved.</p>
                      </div>
                    </div>
                </footer>
            </div>
            <div class="carousel-item" data-id="9">
                <div class="row">
                  <div class="col-sm-12 col-12">
                    <h4 class="font-weight-normal mb-3">Mitapivat Increased PKR Activity and ATP in RBCs from Patients with SCD and <span class="d-inline-block">β-thalassemia</span></h4>
                  </div>
                </div>
                <div class="row">
                    <div class="col-md-12">
                      <ul style="padding-left: 19px;">
                        <li>In ex vivo analyses of RBCs from patients with SCD (HbSS; n=26), HbSC (n=4), β-thalassemia major (N=3, regularly transfused) and 21 healthy controls (HC)<sup>1</sup>:</li>
                      </ul>
                    </div>
                    <div class="col-md-4">
                      <div class="blue-medium white-text text-center border-radius-10 p-3 mb-3">
                        <h6 class="mb-0">PK activity was significantly reduced relative to HK in HbSS and β-thalassemia RBCs compared to healthy controls</h6>
                      </div>

                      <img src="images/mechanism-of-action/11.png" class="w-100 mb-3">
                    </div>
                    <div class="col-md-4">
                      <div class="blue-medium white-text text-center border-radius-10 p-3 mb-3">
                        <h6 class="mb-0">Mitapivat increased PK activity and ATP levels in HbSS and β-thalassemia RBCs and in healthy controls</h6>
                      </div>

                      <img src="images/mechanism-of-action/12.png" class="w-100 mb-3">
                    </div>
                </div>
                <footer>
                    <div class="row">
                      <div class="col-md-6">
                        <p class="text-left mb-4">****p<0.0001, *** p<0.001, ** p<0.01, ns, not significant,<br/>
                          ¥, relative to DMSO control; error bars represent standard deviation<br/>
                          ATP = adenosine triphosphate; PK = pyruvate kinase; HK = hexokinase; HC = healthy controls; HbSC = heterozygous for HbS and HbC; <br/>
                          HbSS = homozygous sickle cell disease; RBC = red blood cell; SCD = sickle cell disease<br/>
                        <strong>1. Rab MAE et al. <i>Poster 3506. 61st ASH Meeting.</i> Orlando, Florida, USA. December 7-10, 2019</strong></p>
                      </div>
                      <div class="col-md-6">
                        <p class="text-right">For more information (physician/HCP only), please email medinfo@agios.com.<br/>
                        &copy;2021 Agios Pharmaceuticals, Inc. All rights reserved.</p>
                      </div>
                    </div>
                </footer>
            </div>
          </div>
        </div>
      </div>
    </main>
    <div class="screensaverDiv d-none">
      <img src="images/screensaver.gif" class="screensaverImg" />
    </div>

    <!-- Optional JavaScript -->
    <!-- jQuery first, then Popper.js, then Bootstrap JS -->
    <!-- <script src="https://code.jquery.com/jquery-3.2.1.slim.min.js" integrity="sha384-KJ3o2DKtIkvYIK3UENzmM7KCkRr/rE9/Qpg6aAZGJwFDMVNA/GpGFF93hXpG5KkN" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.12.9/umd/popper.min.js" integrity="sha384-ApNbgh9B+Y1QKtv3Rn7W3mgPxhU9K/ScQsAP7hUibX39j7fakFPskvXusvfa0b4Q" crossorigin="anonymous"></script> -->
    <script src="js/jquery-3.4.1.min.js"></script>
    <script src="js/bootstrap.min.js"></script>
    <script src="js/screensaver.js"></script>
    <script type="text/javascript">
      //var currentIndex = $('div.active').index();

      $('#mitapivatCarousel').bind('slide.bs.carousel', function() {
        setTimeout(function(){
           var currentIndex = $('.carousel-item.active').data('id');
           console.log(currentIndex);

           if(currentIndex == 1) {
            $('.nav-link.prev').parent('li').hide();
           } else {
            $('.nav-link.prev').parent('li').show();
           }

           if(currentIndex == 9) {
            $('.nav-link.next').parent('li').hide();
           } else {
            $('.nav-link.next').parent('li').show();
           }
        }, 1200);
      });
    </script>
  </body>
</html>